Cargando…

Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study

INTRODUCTION: One of the therapeutic essentials in severe sepsis and septic shock is an adequate fluid replacement to restore and maintain circulating plasma volume, improve organ perfusion and nutritive microcirculatory flow. The type of solution to be used as a fluid replacement remains under disc...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Tim Philipp, Schuerholz, Tobias, Hüter, Lars, Sasse, Michael, Heyder, Florian, Pfister, Wolfgang, Marx, Gernot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396252/
https://www.ncbi.nlm.nih.gov/pubmed/22277099
http://dx.doi.org/10.1186/cc11161
_version_ 1782238088921088000
author Simon, Tim Philipp
Schuerholz, Tobias
Hüter, Lars
Sasse, Michael
Heyder, Florian
Pfister, Wolfgang
Marx, Gernot
author_facet Simon, Tim Philipp
Schuerholz, Tobias
Hüter, Lars
Sasse, Michael
Heyder, Florian
Pfister, Wolfgang
Marx, Gernot
author_sort Simon, Tim Philipp
collection PubMed
description INTRODUCTION: One of the therapeutic essentials in severe sepsis and septic shock is an adequate fluid replacement to restore and maintain circulating plasma volume, improve organ perfusion and nutritive microcirculatory flow. The type of solution to be used as a fluid replacement remains under discussion. The aim of the study was to evaluate the effects of clinically used fluid replacement solutions on renal function and inflammatory response. METHODS: A total of 23 anesthetized and ventilated female German Landrace pigs were investigated over 19 hours using a two-hit model that combined hemorrhagic and septic shock. The septic shock was induced using an Escherichia coli laden clot placed into the abdominal cavity. Infusions of 6% hydroxyethylstarch 130/0.42 in acetate (6% HES 130), 4% gelatin in acetate (4% gelatin) and 10% hydroxyethylstarch 200/0.5 in saline (10% HES200) compared to Ringer's acetate (RAc) were used for fluid replacement to maintain a central venous pressure of 12 mmHg. Ringer's acetate was also used in the sham-treated group (SHAM). RESULTS: At study end the cardiac output (10% HES200 143 ± 48 ml/kgBW; 6% HES130 171 ± 47 ml/kgBW; RAc 137 ± 32 ml/kgBW; 4% gelatin 160 ± 42 ml/kgBW), as well as mean arterial pressure did not differ between groups. N-acetyl-beta-D-glucosamidase was significantly higher in the hydroxyethylstarch 200 (157 ± 115 U/g creatinine; P < 0.05) group compared to hydroxyethylstarch 130 (24 ± 9 U/g creatinine), Ringer's acetate (2 ± 3 U/g creatinine) and SHAM (21 ± 15 U/g creatinine) at the study's end. Creatinine significantly increased by 87 ± 84 percent of baseline in the 10% HES200 group compared to RAc and 6% HES130. We demonstrated in the histology of the kidneys a significant increase in osmotic-nephrosis like lesions for 4% gelatin compared to RAc, 6% HES130 and SHAM. Urine output was lowest in the 10% HES200 and 4% gelatin group, however not significantly. Interleukin(IL)-6 levels were significantly elevated in the 10% HES200 group (3,845 ± 1,472 pg/ml) two hours after sepsis induction compared to all other groups (6% HES130 1,492 ± 604 pg/ml; RAc 874 ± 363 pg/ml; 4% gelatin 1,623 ± 1,242 pg/ml). CONCLUSIONS: Despite similar maintenance of macrocirculation 6% hydroxyethylstarch 130/0.42 and Ringer's acetate significantly preserve renal function and attenuate tubular damage better than 10% hydroxyethylstarch 200/0.5 in saline.
format Online
Article
Text
id pubmed-3396252
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33962522012-07-13 Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study Simon, Tim Philipp Schuerholz, Tobias Hüter, Lars Sasse, Michael Heyder, Florian Pfister, Wolfgang Marx, Gernot Crit Care Research INTRODUCTION: One of the therapeutic essentials in severe sepsis and septic shock is an adequate fluid replacement to restore and maintain circulating plasma volume, improve organ perfusion and nutritive microcirculatory flow. The type of solution to be used as a fluid replacement remains under discussion. The aim of the study was to evaluate the effects of clinically used fluid replacement solutions on renal function and inflammatory response. METHODS: A total of 23 anesthetized and ventilated female German Landrace pigs were investigated over 19 hours using a two-hit model that combined hemorrhagic and septic shock. The septic shock was induced using an Escherichia coli laden clot placed into the abdominal cavity. Infusions of 6% hydroxyethylstarch 130/0.42 in acetate (6% HES 130), 4% gelatin in acetate (4% gelatin) and 10% hydroxyethylstarch 200/0.5 in saline (10% HES200) compared to Ringer's acetate (RAc) were used for fluid replacement to maintain a central venous pressure of 12 mmHg. Ringer's acetate was also used in the sham-treated group (SHAM). RESULTS: At study end the cardiac output (10% HES200 143 ± 48 ml/kgBW; 6% HES130 171 ± 47 ml/kgBW; RAc 137 ± 32 ml/kgBW; 4% gelatin 160 ± 42 ml/kgBW), as well as mean arterial pressure did not differ between groups. N-acetyl-beta-D-glucosamidase was significantly higher in the hydroxyethylstarch 200 (157 ± 115 U/g creatinine; P < 0.05) group compared to hydroxyethylstarch 130 (24 ± 9 U/g creatinine), Ringer's acetate (2 ± 3 U/g creatinine) and SHAM (21 ± 15 U/g creatinine) at the study's end. Creatinine significantly increased by 87 ± 84 percent of baseline in the 10% HES200 group compared to RAc and 6% HES130. We demonstrated in the histology of the kidneys a significant increase in osmotic-nephrosis like lesions for 4% gelatin compared to RAc, 6% HES130 and SHAM. Urine output was lowest in the 10% HES200 and 4% gelatin group, however not significantly. Interleukin(IL)-6 levels were significantly elevated in the 10% HES200 group (3,845 ± 1,472 pg/ml) two hours after sepsis induction compared to all other groups (6% HES130 1,492 ± 604 pg/ml; RAc 874 ± 363 pg/ml; 4% gelatin 1,623 ± 1,242 pg/ml). CONCLUSIONS: Despite similar maintenance of macrocirculation 6% hydroxyethylstarch 130/0.42 and Ringer's acetate significantly preserve renal function and attenuate tubular damage better than 10% hydroxyethylstarch 200/0.5 in saline. BioMed Central 2012 2012-01-25 /pmc/articles/PMC3396252/ /pubmed/22277099 http://dx.doi.org/10.1186/cc11161 Text en Copyright ©2012 Simon et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Simon, Tim Philipp
Schuerholz, Tobias
Hüter, Lars
Sasse, Michael
Heyder, Florian
Pfister, Wolfgang
Marx, Gernot
Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
title Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
title_full Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
title_fullStr Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
title_full_unstemmed Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
title_short Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
title_sort impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396252/
https://www.ncbi.nlm.nih.gov/pubmed/22277099
http://dx.doi.org/10.1186/cc11161
work_keys_str_mv AT simontimphilipp impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy
AT schuerholztobias impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy
AT huterlars impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy
AT sassemichael impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy
AT heyderflorian impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy
AT pfisterwolfgang impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy
AT marxgernot impairmentofrenalfunctionusinghyperoncoticcolloidsinatwohitmodelofshockaprospectiverandomizedstudy